First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow Conversion Efficiency
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued cash flow conversion efficiency. Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($257.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Cash flow conversion efficiency of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's cash flow conversion efficiency has evolved over time, based on yearly financial data. View First Tracks Biotherapeutics, Inc. Ordin (TRAXV) stock price for real-time trading data and today's change.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow Conversion Ratio Explained
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued ranked by their cash flow conversion efficiency. Also see First Tracks Biotherapeutics, Inc. Ordin (TRAXV) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Betterware de México, S.A.P.I. de C.V.
NYSE:BWMX
|
0.270x |
|
Tai-Tech Advanced Electronics Co Ltd
TWO:3357
|
0.022x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
Cera Sanitaryware Limited
NSE:CERA
|
0.052x |
|
Hangzhou Huawang New Material Technology Co.Ltd.
SHG:605377
|
0.025x |
|
Cass Information Systems Inc
NASDAQ:CASS
|
0.060x |
|
Beijing Telesound Electronics Co Ltd
SHE:003004
|
0.017x |
|
Beijing SDL Technology Co Ltd
SHE:002658
|
0.056x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. Review how financially flexible is First Tracks Biotherapeutics, Inc. Ordin to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more